Roche Clinical trial

Roche and Genentech (the US member of the Roche group) have now recruited their first patient for the “Tangelo” clinical trial which is a Phase 1 open-label trial to investigate the safety, tolerability, pharmacokinetics & pharmacodynamics of RO7248824.   The study will recruit 66 individuals with either a mutation or deletion between the ages of one and twelve years.